Search Results - "Stanek, Eric" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis

by Gotlib, Jason, Kluin-Nelemans, Hanneke C, George, Tracy I, Akin, Cem, Sotlar, Karl, Hermine, Olivier, Awan, Farrukh T, Hexner, Elizabeth, Mauro, Michael J, Sternberg, David W, Villeneuve, Matthieu, Huntsman Labed, Alice, Stanek, Eric J, Hartmann, Karin, Horny, Hans-Peter, Valent, Peter, Reiter, Andreas
Published in The New England journal of medicine (30.06.2016)

Get full text

Journal Article

Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness

Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness

by Taylor, Allen J, Villines, Todd C, Stanek, Eric J, Devine, Patrick J, Griffen, Len, Miller, Michael, Weissman, Neil J, Turco, Mark
Published in The New England journal of medicine (26.11.2009)

Get full text

Journal Article

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration

by VILLINES, Todd C, STANEK, Eric J, DEVINE, Patrick J, TURCO, Mark, MILLER, Michael, WEISSMAN, Neil J, GRIFFEN, Len, TAYLOR, Allen J
Published in Journal of the American College of Cardiology (15.06.2010)

Get full text

Journal Article

Twelve-Month Frequency of Drug-Metabolizing Enzyme and Transporter-Based Drug-Drug Interaction Potential in Patients Receiving Oral Enzyme-Targeted Kinase Inhibitor Antineoplastic Agents

Twelve-Month Frequency of Drug-Metabolizing Enzyme and Transporter-Based Drug-Drug Interaction Potential in Patients Receiving Oral Enzyme-Targeted Kinase Inhibitor Antineoplastic Agents

by Bowlin, Steven J., DO, MPH, PhD, Xia, Fang, PhD, Wang, Wenyi, MS, Robinson, Keisha D., MBA, MPM, Stanek, Eric J., PharmD
Published in Mayo Clinic proceedings (01.02.2013)

Get full text

Journal Article

Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study

Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study

by Kreutz, Rolf P, Stanek, Eric J, Aubert, Ronald, Yao, Jianying, Breall, Jeffrey A, Desta, Zeruesenay, Skaar, Todd C, Teagarden, J Russell, Frueh, Felix W, Epstein, Robert S, Flockhart, David A
Published in Pharmacotherapy (01.08.2010)

Get more information

Journal Article

Sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials

Sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials

by Charland, Scott L, Stanek, Eric J
Published in Pharmacotherapy (01.05.2014)

Get more information

Journal Article

Healthcare resource utilization and cost of obstructive hypertrophic cardiomyopathy in a US population

Healthcare resource utilization and cost of obstructive hypertrophic cardiomyopathy in a US population

by Butzner, Michael, Maron, Martin, Sarocco, Phil, Teng, Chia-Chen, Stanek, Eric, Tan, Hiangkiat, Robertson, Laura
Published in American heart journal plus (01.01.2022)

Get full text

Journal Article

On pharmacogenomics in pharmacy benefit management

On pharmacogenomics in pharmacy benefit management

by Russell Teagarden, J, Stanek, Eric J
Published in Pharmacotherapy (01.02.2012)

Get more information

Journal Article

Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe

Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe

by Taylor, Allen J, Villines, Todd C, Stanek, Eric J
Published in European heart journal (01.12.2012)

Get full text

Journal Article

An Internet-based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users

An Internet-based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users

by Warriner, Amy H, Outman, Ryan C, Allison, Jeroan J, Curtis, Jeffrey R, Markward, Nathan J, Redden, David T, Safford, Monika M, Stanek, Eric J, Steinkellner, Amy R, Saag, Kenneth G
Published in Journal of rheumatology (01.08.2015)

Get more information

Journal Article

Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study

Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study

by Collet, Jean-Philippe, Hulot, Jean-Sébastien, Abtan, Jérémie, Anzaha, Ghalia, Kerneis, Mathieu, Silvain, Johanne, Cayla, Guillaume, O’Connor, Stephen A., Barthélémy, Olivier, Beygui, Farzin, Galier, Sophie, Brugier, Delphine, Stanek, Eric J., Charland, Scott L., Gallois, Vanessa, Montalescot, Gilles
Published in European journal of clinical pharmacology (01.09.2014)

Get full text

Journal Article

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information

by Stanek, Eric J, Sanders, Christopher L, Frueh, Felix W
Published in Journal of personalized medicine (10.06.2013)

Get full text

Journal Article

Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting

Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting

by MOSCA, Lori, MERZ, Noel Bairey, BLUMENTHAL, Roger S, CZIRAKY, Mark J, FABUNMI, Rosalind P, SARAWATE, Chaitanya, WATSON, Karol E, WILLEY, Vincent J, STANEK, Eric J
Published in Circulation (New York, N.Y.) (01.02.2005)

Get full text

Journal Article

Risk of cardiovascular events in patients at optimal values for combined lipid parameters

Risk of cardiovascular events in patients at optimal values for combined lipid parameters

by Stanek, Eric J., Sarawate, Chaitanya, Willey, Vincent J., Charland, Scott L., Cziraky, Mark J.
Published in Current medical research and opinion (01.03.2007)

Get full text

Journal Article

PATIENT KNOWLEDGE OF PHARMACOGENETIC INFORMATION IMPROVES ADHERENCE TO STATIN THERAPY: RESULTS OF THE ADDITIONAL KIF6 RISK OFFERS BETTER ADHERENCE TO STATINS (AKROBATS) TRIAL

PATIENT KNOWLEDGE OF PHARMACOGENETIC INFORMATION IMPROVES ADHERENCE TO STATIN THERAPY: RESULTS OF THE ADDITIONAL KIF6 RISK OFFERS BETTER ADHERENCE TO STATINS (AKROBATS) TRIAL

by Charland, Scott L, Agatep, Barnabie C, Epstein, Robert S, Frueh, Felix W, Herrera, Vivian, Devlin, James, Superko, H, Stanek, Eric J
Published in Journal of the American College of Cardiology (27.03.2012)

Get full text

Journal Article

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)

by Villines, Todd C., MD, Stanek, Eric J., PharmD, Devine, Patrick J., MD, Turco, Mark, MD, Miller, Michael, MD, Weissman, Neil J., MD, Griffen, Len, MD, Taylor, Allen J., MD
Published in Journal of the American College of Cardiology (01.06.2010)

Get full text

Journal Article

Flushing and the HDL-C response to extended-release niacin

Flushing and the HDL-C response to extended-release niacin

by Taylor, Allen J., MD, Stanek, Eric J., PharmD
Published in Journal of clinical lipidology (01.08.2008)

Get full text

Journal Article

Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?

Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?

by Sarawate, Chaitanya A., MS, Cziraky, Mark J., PharmD, Stanek, Eric J., PharmD, Willey, Vincent J., PharmD, Corbelli, John C., MD, Charland, Scott L., PharmD
Published in Clinical therapeutics (2007)

Get full text

Journal Article

Dietary Supplement Use in Patients Enrolled in the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) Trial

Dietary Supplement Use in Patients Enrolled in the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) Trial

by Charland, Scott L., PharmD, Agatep, Barnabie, MPH, Schrader, Bruce, PharmD, Markward, Nathan, PhD, MPH, Frueh, Felix, PhD, Epstein, Robert, MD, Devlin, James, PhD, Superko, Robert, MD, Stanek, Eric, PharmD
Published in Journal of clinical lipidology (01.05.2011)

Get full text

Journal Article

Real-World Evaluation of Lipid Testing Rate and Treatment Target Attainment Among High-Risk Patients: Post Release of the 2018 AHA/ACC Practice Guidelines

Real-World Evaluation of Lipid Testing Rate and Treatment Target Attainment Among High-Risk Patients: Post Release of the 2018 AHA/ACC Practice Guidelines

by Visaria, Jay, Stanek, Eric, White, Jeff, Cziraky, Mark, Gangan, Nilesh
Published in Journal of clinical lipidology (01.07.2024)

Get full text

Journal Article